ESPR vs SRE · rev $332.3M vs P/E 31, rev $13.70B
Esperion Therapeutics Inc (ESPR) versus Sempra Energy (SRE) — a side-by-side from cached financials, not a winner call.
Esperion Therapeutics Inc (ESPR) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Sempra Energy (SRE) is a utilities - diversified company listed on US.
Latest reported ESPR revenue for 2024-12-31 was $332.3M. Net income was -$51.7M. Revenue was up 185.7% from 2023-12-31 to 2024-12-31. ESPR currently screens at market cap $816.9M.
Latest reported SRE revenue for 2025-12-31 was $13.70B. Net income was $1.84B. Revenue was up 3.9% from 2024-12-31 to 2025-12-31. SRE currently screens at market cap $59.76B and trailing P/E 31.1.
ESPR currently screens at market cap $816.9M. SRE currently screens at market cap $59.76B and trailing P/E 31.1.
Not investment advice. Open the ESPR and SRE stock pages for the full models.
Not investment advice.